PTC Therapeutics | PTCT - Interest Expense On Debt


PTC Therapeutics reported $2.87B in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Alnylam Pharmaceuticals USD 69.29M 60.05M Mar/2026
Amgen USD 657M 4M Mar/2026
BioCryst Pharmaceuticals USD 14.14M 5.53M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 14.96M 12.18M Mar/2026
Cytokinetics USD 33.34M 3M Mar/2026
Daiichi Sankyo JPY 2.16B 1.33B Dec/2025
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
Esperion Therapeutics USD 22.64M 585K Dec/2025
Gilead Sciences USD 240M 15M Mar/2026
Incyte USD 569K 13K Mar/2026
Ionis Pharmaceuticals USD 17M 1000K Mar/2026
Ironwood Pharmaceuticals USD 8.74M 506K Dec/2024
Karyopharm Therapeutics USD 12.62M 1.24M Dec/2025
Novartis USD 343M 39M Mar/2026
Pfizer USD 671M 40M Mar/2026
PTC Therapeutics USD 2.87B 2.82B Mar/2026
Puma Biotechnology USD 3.37M 11K Jun/2024
Roche Holding CHF 304M 7.5M Jun/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sarepta Therapeutics USD 20.84M 13.28M Dec/2025
TG Therapeutics USD 7.67M 1.13M Mar/2026
Ultragenyx Pharmaceutical USD 21M 2M Mar/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025
Xencor USD 4.7M 2.65M Mar/2026